AirSculpt Technologies Inc.

Company Overview

Business Model: AirSculpt Technologies, Inc. offers next-generation body contouring treatments exclusively at its AirSculpt offices. The core value proposition is a minimally invasive procedure that removes fat and tightens skin, sculpting targeted body areas with no needle, no scalpel, no stitches, and no general anesthesia, allowing for quick healing and precise results. Revenue is generated from these procedures, which are 100% self-pay, with patients often utilizing third-party financing options. The Company operates as a holding company, providing administrative, management, and business support services to Professional Associations, which are owned by licensed surgeons responsible for clinical operations.

Market Position: AirSculpt Technologies, Inc. operates within the large and growing body fat reduction market, estimated at $11 billion in 2022 with a projected 9% compound annual growth rate through 2027. The Company positions itself as a preferred body contouring brand, leveraging its proprietary and patented AirSculpt method, which is differentiated by its minimally invasive nature and customized results. Competitive strengths include a broad offering of innovative procedures (e.g., Power BBL, Up a Cup, Hip Flip, CankCure, AirSculpt+, AirSculpt Smooth), a premium patient experience in spa-like environments, and a network of highly skilled surgeons. The Company faces competition from traditional surgical procedures, other minimally-invasive techniques, and non-surgical weight loss solutions, including weight-loss drugs.

Recent Strategic Developments: In fiscal year 2025, AirSculpt Technologies, Inc. focused on new product innovation, including expanding its skin tightening procedure as a standalone offering. The Company also introduced AirSculpt+ and AirSculpt Smooth in fiscal year 2022. In response to revenue declines in 2024 and 2025, the Company is implementing cost-savings initiatives, optimizing marketing investments, strengthening sales execution, and expanding consumer financing options. Near-term plans include a pause on new center and procedure room openings to improve liquidity.

Geographic Footprint: As of March 31, 2026, AirSculpt Technologies, Inc. operates 31 centers across 20 U.S. states and Canada. These centers are primarily located in affluent metropolitan and suburban areas. The Company closed its London facility in the United Kingdom during fiscal year 2025 due to financial performance.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 59.4%
• Operating Margin: -7.6%
• Net Margin: -7.7%

Investment in Growth:

• Capital Expenditures: $2.4 million
• Strategic Investments: The Company recorded a $4.5 million loss related to the impairment of a portion of its Salesforce implementation project in 2025.

Business Segment Analysis

Direct Medical Procedure Services

Financial Performance:

• Revenue: $151.8 million (-15.8% YoY)
• Operating Margin: -7.6%
• Key Growth Drivers: Patient demand influenced by consumer confidence, disposable income, availability of financing, perceived advantages of AirSculpt procedures, and the success of sales and marketing programs. The Company aims to drive growth through new, innovative procedures, increased prices, optimized marketing investment, and expanded consumer financing options.

Product Portfolio:

• Major product lines and services include fat removal procedures across various treatment areas, and innovative fat transfer procedures such as Power BBL (Brazilian Butt Lift), Up a Cup Breast Augmentation, and Hip Flip (hourglass contouring).
• New product launches or major updates: AirSculpt+ (permanently removes fat and tightens skin) and AirSculpt Smooth (cellulite reduction) were introduced in 2022. The CankCure procedure (calf and ankle contouring) was introduced in 2020. In 2025, the Company focused on new product innovation, including expanding its skin tightening procedure as a standalone offering.

Market Dynamics:

• Competitive positioning within segment: AirSculpt Technologies, Inc. differentiates itself through its patented, minimally invasive AirSculpt method, which requires no needle, no scalpel, no stitches, and no general anesthesia.
• Key customer types and market trends: Patients are 100% self-pay, often from affluent metropolitan and suburban areas. Market trends include increased self-image awareness, social acceptance of cosmetic treatments, improved safety and recovery profiles of procedures, rising disposable income, and the increasing prevalence of overweight and obesity. The increasing use of GLP-1 weight loss drugs may also lead to increased demand for body contouring and skin tightening procedures.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: No dividends were declared or paid on common stock during the twelve months ended December 31, 2025. The Company currently intends to retain all available funds and future earnings and does not anticipate paying any cash dividends in the foreseeable future.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $8.4 million
• Total Debt: $57.0 million (principal amount of term loans)
• Net Cash Position: $(48.5) million (net debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: $5.5 million due in 2026, and $51.5 million due in 2027. The Term Loan and Revolving Credit Facility mature on May 11, 2027.

Cash Flow Generation (for the year ended December 31, 2025):

• Operating Cash Flow: $3.1 million
• Free Cash Flow: $0.7 million (Operating Cash Flow less Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: AirSculpt Technologies, Inc. delivers its body contouring procedures through a proprietary, patented method that is minimally invasive, performed in one session while the patient is awake, and requires no needle, no scalpel, no stitches, and no general anesthesia. Procedures are performed by trained surgeons for customized and precise results, aiming for quick healing with minimal bruising and tighter skin. The Company's centers are accredited as office-based practices under The Joint Commission, demonstrating a commitment to safety and quality.

Supply Chain Architecture: Key Suppliers & Partners:

• Handpiece Manufacturer: Euromi S.A. (a Belgian company) manufactures the FDA-approved handpiece used in AirSculpt procedures. AirSculpt Technologies, Inc. relies on this single third-party manufacturer.
• Other Parts: Other FDA-approved parts, such as cannulas and vacuum pumps, are sourced from other manufacturers, with some customized for AirSculpt Technologies, Inc. by its suppliers.

Facility Network:

• Corporate Headquarters: Located in Miami Beach, Florida, occupying approximately 3,714 rentable square feet, used for sales and marketing, IT, social media content management, research and development, supply chain, logistics, finance, HR, and AirSculpt TV editing.
• Manufacturing: Not applicable; the Company outsources manufacturing of key tools.
• Research & Development: R&D activities are conducted at the corporate headquarters, focusing on innovating procedures to be easier to perform, deliver enhanced results, and be more pleasant for patients.
• Distribution: As of March 31, 2026, the Company operates 31 centers across 20 U.S. states and Canada. Each center is approximately 3,000 to 5,000 square feet, typically contains two procedure rooms, and has the capacity to perform up to 36 surgeries per week.

Operational Metrics (for the year ended December 31, 2025):

• Cases performed: 11,852
• Revenue per case: $12,809

Market Access & Customer Relationships

Go-to-Market Strategy: AirSculpt Technologies, Inc. employs an in-house marketing team focused on digital and other platforms. This includes search engine optimization, managing social media presence (Facebook, Instagram, YouTube), and developing digital content like a vast "before and after" photo gallery and "AirSculpt TV" to showcase treatment outcomes and patient testimonials. The Company also utilizes celebrity and influencer endorsements and word-of-mouth referrals.

Distribution Channels:

• Direct Sales: Sales assistants respond to inquiries, schedule virtual or in-person consultations, and guide patients through the process. Surgeons and patient care consultants engage directly with patients.
• Channel Partners: The Company assists patients in securing third-party financing from entities such as CareCredit, PatientFi, and Alphaeon. Approximately 50% of cases in 2025 involved third-party financing.
• Digital Platforms: Online sales channels and e-commerce initiatives are driven by web-based lead generation, resulting in over 625,000 monthly website visits, primarily through optimized Google marketing spend.

Customer Portfolio:

• Enterprise Customers: Not applicable; the Company serves individual patients directly.
• Strategic Partnerships: Partnerships with third-party financing vendors are crucial for customer accessibility.
• Customer Concentration: Five centers located in California represented 20% of the Company's revenue in both 2025 and 2024, indicating a concentration risk in that region.

Geographic Revenue Distribution (for the year ended December 31, 2025):

• International Revenue: $4.6 million
• Growth Markets: The Company believes there is a significant North American growth opportunity of over 200 potential locations in the U.S. and Canada, which it will continue to opportunistically evaluate for new center openings in the long term.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Company operates in the large and growing market for body fat reduction procedures, which was estimated at $11 billion in 2022 and is expected to grow at a 9% compound annual growth rate through 2027. Key trends driving this market include increased consumer self-image awareness (driven by social media), reduced social stigma around cosmetic treatments, improved safety and recovery profiles due to technological advances, a global rise in disposable income, and increasing weight gain in the overall population. The increasing use of GLP-1 weight loss drugs may also lead to increased demand for body contouring and skin tightening procedures.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Individual and small practice group providers: Offer traditional liposuction, which the Company believes requires longer patient recovery times.
• National providers of other minimally-invasive techniques: The Company believes these are less effective than the AirSculpt method.
• University and hospital systems, medical spas, and beauty and rejuvenation centers: Offer body contouring services as part of their broader offerings.
• Companies offering non-surgical methods of fat reduction: Includes weight-loss drugs and other non-invasive weight loss and obesity solutions.

Emerging Competitive Threats: New entrants, disruptive technologies, and the increased market acceptance, availability, and customer awareness of weight-loss drugs (e.g., GLP-1s) pose a significant competitive threat, although they may also drive demand for complementary body contouring and skin tightening procedures.

Competitive Response Strategy: AirSculpt Technologies, Inc. aims to maintain its competitive advantage by continuously enhancing its current procedures and technologies, developing and marketing new procedures, growing brand awareness, optimizing marketing investments, and expanding consumer financing options.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The market for elective cosmetic procedures is sensitive to consumer confidence, disposable income, and the availability of financing. The increasing use of weight-loss drugs could impact demand for fat reduction procedures.
• Technology Disruption: The aesthetic body contouring market is characterized by rapid technological change. Failure to maintain the superiority of the AirSculpt method or adapt to new, more effective, or less invasive competitor technologies could harm the business.
• Customer Concentration: Five centers in California accounted for 20% of revenue in 2025 and 2024, exposing the Company to adverse economic or regulatory developments in that region.
• Geopolitical Exposure: Disruptions in the global economy due to geopolitical instability (e.g., Russia-Ukraine conflict, Middle East conflict, U.S.-China tensions) could negatively impact global demand, supply chains, and costs.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Reliance on a single third-party manufacturer (Euromi S.A.) for key handpiece components makes the Company vulnerable to supply shortages, price fluctuations, and quality control issues.
• Capacity Constraints: Rapid growth could strain existing operational, managerial, and administrative resources, leading to difficulties in hiring, training, and managing surgeons and staff.
• Medical Liability Claims: The nature of the services provided could lead to medical liability claims against Professional Associations and surgeons, potentially exceeding insurance coverage.
• Cybersecurity Breaches: Dependence on information technology systems and the processing of sensitive patient data expose the Company to risks of cyber-attacks, data breaches, and system disruptions, which could result in significant costs, liabilities, and reputational harm.
• Paper Medical Records: Continued reliance on paper medical records increases the risk of loss, destruction, human error, and potential privacy breaches.

Financial & Regulatory Risks

• Market & Financial Risks: High leverage ($57.0 million in principal debt as of December 31, 2025) and variable rate debt expose the Company to interest rate risk and limit financial flexibility. Restrictive covenants in debt instruments could adversely affect operations.
• Regulatory & Compliance Risks: The cosmetic treatment industry is heavily regulated by federal, state, and local laws concerning licensing, accreditation, corporate practice of medicine (CPOM), fee-splitting, healthcare fraud and abuse (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), and data privacy (e.g., CCPA, CPRA, CMIA, PCI DSS). Changes in these laws or interpretations, or non-compliance, could result in significant penalties, operational changes, or loss of licenses.
• Antitrust Laws: Potential for enforcement actions if market share is deemed too concentrated or if antitrust laws are violated.

Geopolitical & External Risks

• Government Shutdowns: Disruptions at government agencies like the FDA and SEC due to funding shortages or shutdowns could negatively impact business operations and regulatory interactions.
• Natural Disasters/Pandemics: Adverse weather conditions, natural disasters, or outbreaks of contagious diseases could disrupt patient scheduling, force center closures, and cause staffing shortages.

Innovation & Technology Leadership

Research & Development Focus: AirSculpt Technologies, Inc. emphasizes continuous innovation to enhance its body contouring procedures. The Company's R&D efforts focus on making the AirSculpt procedure easier to perform, delivering enhanced results, and improving the patient experience. This includes the novel introduction of the AirSculpt method and the expansion and refinement of its procedure portfolio, such as the development of fat transfer procedures (Power BBL, Up a Cup, Hip Flip), and the introduction of AirSculpt+ and AirSculpt Smooth.

Intellectual Property Portfolio:

• Patent Strategy: The Company's patent portfolio includes two issued U.S. utility patents, one pending U.S. utility patent application, one pending U.S. provisional patent application, one pending U.S. design patent application, one pending Canada utility patent application, and one pending U.K. utility patent application. These patents protect proprietary implementations of the AirSculpt process and the combination of multiple components to form proprietary systems. Issued patents are expected to expire in 2033 or later.
• Trademark Strategy: AirSculpt Technologies, Inc. relies on a strong portfolio of U.S. registered trademarks and pending registrations, including AirSculpt®, AirSculpt+®, AirSculpting®, Elite Body Sculpture®, Power BBL®, Up a Cup™, Hip Flip®, CankCure®, and its 'hourglass' logo, to distinguish its procedures and services.

Technology Partnerships: The Company uses an FDA-approved handpiece manufactured by Euromi S.A., a Belgian company specializing in medical, dermatological, and plastic surgery products.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Todd Magazine stepped down as CEO on August 8, 2024, and Yogi Jashnani assumed the role. The Company's ability to attract and retain qualified management personnel is crucial for future success.

Board Composition: The Board of Directors includes a Non-Executive Chairman, Michael Doyle, and directors Adam Feinstein, Daniel Sollof, Caroline Chu, Thomas Aaron, and Kenneth Higgins. The Audit Committee Chair holds a Certification in Cybersecurity Oversight from the National Association of Corporate Directors. Vesey Street Capital Partners, L.L.C., the Company's private equity sponsor, beneficially owns 47% of common stock and holds contractual rights to Board seats.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: Approximately 330 full-time and 33 part-time employees.
• Geographic Distribution: Employees are dispersed across various geographic regions where the Company's centers are located.
• Skill Mix: The workforce includes licensed medical professionals such as physicians and nurses, as well as office managers, sales consultants, sales assistants, and front desk concierges. Approximately 90 surgeons are contracted.

Talent Management:

• Acquisition & Retention: The Company faces intense competition for skilled surgeons and other medical professionals. Recruitment is a selective process, with prospective surgeons undergoing an "Elite Fellowship Program" for proprietary AirSculpt training. The Company offers a compelling economic opportunity for surgeons, with annual compensation for part-time work often higher than average full-time private practice salaries.
• Employee Value Proposition: Not explicitly detailed beyond surgeon compensation.

Diversity & Development: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: AirSculpt procedures are elective and 100% self-pay, meaning costs are borne directly by the patient and are not covered by government or private health insurance. Patient demand is influenced by factors such as general consumer confidence, individual disposable income levels, the continued availability of third-party financing, the cost-effectiveness and safety of AirSculpt procedures relative to alternatives, patient expectations, and consumer sentiment regarding aesthetic procedures. The Company's use of social media and ability to offer virtual consultations also influence demand.

Planning & Forecasting: The Company's limited operating history at its current scale and the rapidly evolving nature of the body contouring market, coupled with economic factors, make it difficult to accurately forecast quarterly or annual revenue.

Regulatory Environment & Compliance

Regulatory Framework: AirSculpt Technologies, Inc. operates in a highly regulated healthcare industry, subject to numerous federal, state, and local laws and regulations.

• Industry-Specific Regulations: These include requirements for center licensing, accreditation (e.g., The Joint Commission), certification, medical care adequacy, equipment, personnel, operating policies, medical record maintenance, and environmental protection.
• Corporate Practice of Medicine and Fee-Splitting Laws: Many states prohibit non-physician entities from practicing medicine or engaging in fee-splitting. The Company's structure, involving Management Services Agreements with Professional Associations owned by licensed surgeons, is designed to comply with these laws, but interpretations can vary and change, potentially requiring restructuring or incurring penalties.
• Healthcare Fraud and Abuse Laws: Although services are not government-reimbursed, the Company may be subject to federal and state anti-kickback, self-referral, false claims, and fraud laws, as well as consumer protection and advertising laws.
• Antitrust Laws: The Company is subject to federal and state antitrust laws prohibiting anti-competitive conduct, with enforcement in the healthcare industry being a priority for the Federal Trade Commission.

Trade & Export Controls: Not explicitly detailed beyond general geopolitical risks.

Legal Proceedings: The Company is routinely involved in legal actions and proceedings, primarily medical malpractice claims related to services provided by Professional Associations and affiliated physicians. Other potential claims include personal injury, professional liability, billing and marketing practices, employment disputes, and contractual claims. While insurance coverage is maintained, there is no assurance it will be adequate for all liabilities.

Tax Strategy & Considerations

Tax Profile: AirSculpt Technologies, Inc. is subject to income taxation at federal, state, and foreign levels. For the year ended December 31, 2025, the effective tax rate was (33.8)%, compared to (2.3)% in 2024 and 249.4% in 2023. A main driver of the difference between the effective and statutory rates is non-deductible executive compensation under Section 162(m) of the Internal Revenue Code. As of December 31, 2025, the Company had federal, state, and foreign net operating loss carryforwards of $9.6 million, $13.6 million, and $0.8 million, respectively.

Tax Reform Impact: The Company is subject to potential impacts from future guidance related to the Tax Cuts and Jobs Act of 2017, state conformity to federal tax legislation, and proposals from the U.S. Congress and the Organization for Economic Cooperation and Development (OECD) regarding the taxation of multinational corporations.

Insurance & Risk Transfer

Risk Management Framework: AirSculpt Technologies, Inc. maintains various insurance coverages to mitigate risks.

• Insurance Coverage: Professional and general liability insurance provides coverage ranging from $0.5 million to $2.0 million per occurrence, with a $50,000 retention per occurrence, and an annual aggregate coverage of $1.0 million to $4.0 million. The Company also holds business interruption insurance, property damage insurance, and an additional umbrella insurance policy totaling $6.0 million. Directors' and officers' insurance is maintained.
• Risk Transfer Mechanisms: Surgeons providing professional services at the Company's centers are required to maintain separate malpractice coverage with similar minimum coverage limits.